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Abstract
Background: Adequate maternal nutrition during gestation is requisite for fetal nutrition and
development. While a large group of epidemiological studies indicate poor fetal nutrition increases
heart disease risk and mortality in later life, little work has focused on the effects of impaired
maternal nutrition on fetal heart development. We have previously shown that 50% global nutrient
restriction from 28–78 days of gestation (early to mid-pregnancy; term = 147 days) in sheep at mid-
gestation retards fetal growth while protecting growth of heart and results in hypertensive male
offspring at nine months of age. In the present study, we evaluate LV gene transcription using RNA
protection assay and real-time reverse transcriptase polymerase chain reaction, and protein
expression using western blot, of VEGF and AT1 and AT2 receptors for AngII at mid-gestation in
fetuses from pregnant ewes fed either 100% (C) or 50% (NR) diet during early to mid-gestation.
Results:  No difference between the NR (n = 6) and C (n = 6) groups was found in gene
transcription of the AngII receptors. Immunoreactive AT1 (1918.4 +/- 154.2 vs. 3881.2 +/- 494.9;
P < 0.01) and AT2 (1729.9 +/- 293.6 vs. 3043.3 +/- 373.2; P < 0.02) was decreased in the LV of NR
fetuses compared to C fetuses. The LV of fetuses exposed to NR had greater transcription of
mRNA for VEGF (5.42 ± 0.85 vs. 3.05 ± 0.19; P < 0.03) than respective C LV, while no change was
observed in immunoreactive VEGF.
Conclusion: The present study demonstrates that VEGF, AT1 and AT2 message and protein are
not tightly coupled, pointing to post-transcriptional control points in the mid gestation NR fetus.
The present data also suggest that the role of VEGF and the renin-angiotensin system receptors
during conditions inducing protected cardiac growth is distinct from the role these proteins may
play in normal fetal cardiac growth. The present findings may help explain epidemiological studies
that indicate fetuses with low birth weight carry an increased risk of mortality from coronary and
cardiovascular disease, particularly if these individuals have reduced cardiovascular reserve due to
an epigenetic decrease in vascularization.
Background
Adequate maternal nutrition is of the utmost importance
for proper fetal growth and development [1,2]. Epidemi-
ological evidence links impaired maternal nutrition and
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compromised fetal growth to increased incidence of cardi-
ovascular disease in adulthood [3,4]. LV hypertrophy and
increased ventricular wall thickness are generally agreed to
be powerful and independent risk factors for coronary
heart disease, stroke and sudden death. Despite the obser-
vations linking maternal NR and increased mortality from
heart disease in adults, few studies have been published
investigating the effects of maternal NR on the develop-
ment of the fetal myocardium. This rings especially true in
the context of the developmental origins hypothesis
which describes a causal link between poor materno-fetal
nutrition and cardiovascular disease in later life [5], and
in which there is a marked lack of published reports exam-
ining NR-induced changes at the molecular level in the
mid-gestation fetal heart.
Work from our group has reported the development of a
model of global NR encompassing the first half of gesta-
tion in sheep [6]. Several aspects of this model have
already been detailed at 78 dGA, including IUGR with
protected heart growth (as indicated by increased LV to
fetal weight ratio) [6]; altered transcription of numerous
hypertrophy related genes in the fetal cardiac LV [7];
increased incidence of oxidative base lesions in fetal oog-
onia [8]; and altered concentrations of amino acids in
fetal fluids [9]. Moreover, we have recently shown the
same paradigm of global maternal NR during early to
mid-gestation results in altered expression of components
of the renal renin-angiotensin system and hypertension in
offspring at nine months of age [10].
Studies in the rat show that IUGR induced by sodium
restriction during gestation results in several alterations in
gene transcripts and protein expression in hypertensive
adult females [11], but there are no reports to our knowl-
edge detailing possible contributions of alterations in
fetal gene expression to the observed adult phenotype
from this model. Maternal NR during late gestation in
sheep has been show to affect fetal cardiovascular func-
tion by decreasing basal heart rate [12] and increasing
fetal blood pressure [13], however these studies have not
reported changes in gene transcription or protein expres-
sion of any proteins involved in cardiac development.
Distinct patterns of mRNA and protein expression for the
AngII receptors AT1 and AT2 have been noted during
heart development in the sheep [14,15]. Sundgren and
coworkers have demonstrated that angiotensin II (AngII)
mediates hyperplastic but not hypertrophic activity in the
ovine fetal heart [16]. Others have implicated the renin-
angiotensin system in the processes of normal and patho-
logical cardiac growth in both the fetus and adult [17-19].
Likewise, vascular endothelial growth factor (VEGF) is rec-
ognized as an important contributor to normal fetal
growth and development [20]. Moreover, it has recently
been show that VEGF and the renin-angiotensin system
posses an intimate relationship regarding the promotion
of angiogenesis and inflammation [21,22] and that AT1
inhibition impairs VEGF mediated coronary angiogenesis
[23].
Given the association between VEGF, the renin-angi-
otensin system via the AT1 receptor, and protected cardiac
ventricular growth introduced above, and given that we
have suggested that the regulation of fetal LV growth and
development following NR likely involves the two entry
points – VEGF and the AT1 receptor [7], we report here the
results on an investigation of the hypothesis that both
VEGF and the AT1 receptor exhibit increased gene and
protein expression at mid gestation in LV tissue from NR
compared to control fed fetuses.
Methods
Animals and Experimental Groups
Animal protocols were approved by the University of
Wyoming Institutional Animal Care and Use Committee.
The tissues utilized in this study derive from the same
cohort of animals previously published [6-9] whereby
pregnant ewes were fed either a control (C: 100% of
National Research Council suggested rations) or NR (50%
NRC rations) from 28–78 dGA (term = 147 days). Ewes
and fetuses were euthanized at 78 dGA in the manner
described previously [6]. The cohort consisted of twelve
fetuses from eleven pregnancies. Of the eleven pregnan-
cies, five were NR (3 twins, 3 singletons; 4 female, 2 male)
and six were C (3 twins, 3 singletons; 3 female, 3 male).
When possible one fetus was chosen at random from a
twin pregnancy; however in one case two males from a
twin pregnancy were utilized in an attempt to maximize
the number of males in the NR group.
Tissue Collection
Fetal hearts were excised, cleansed of connective tissues,
blotted dry and weights were recorded. Fetal left ventricles
were dissected, quickly weighed, snap frozen and stored at
-80°C for later analysis.
Protein and RNA Extraction
Total soluble protein and RNA were extracted from the left
ventricles as detailed previously [10,24].
Ribonuclease Protection Assays (RPA)
RPAs were performed to examine relative levels of tran-
script for VEGF. All samples were evaluated in a single
assay. The cDNA probes for ovine VEGF were graciously
provided by Dr. Dale Redmer (North Dakota State Uni-
versity, Fargo, ND) and have been detailed previously
[25]. The cDNA probe for the housekeeping gene β-actin,
pActn9, was constructed in our laboratory using the fol-
lowing primers: ACC GTG AAA AGA TGA CCC AG, and
GCT GTA CCA CAT CTG CTG GA by reverse transcriptionReproductive Biology and Endocrinology 2005, 3:27 http://www.rbej.com/content/3/1/27
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PCR. The pActn9 sequence was validated by sequence
analysis to ensure alignment with the ovine β-actin
sequence (accession# AF035422).
The RPAs were conducted as per manufacturer's directions
using 20 µg of total mRNA with β-actin used as the house-
keeping gene. Radio-labeled [a-32P] antisense probes were
synthesized by in vitro transcription using either T3 or T7
polymerases (Ambion, Austin, TX) in the presence of
unlabeled nucleoside triphosphates and gel purified. Fol-
lowing RNase digestion, the hybridization products were
ethanol precipitated and separated by electrophoresis.
The gel was vacuum dried on to filter paper and exposed
to X-ray film. Band sizes were determined with radio-
labeled size markers generated with an in vitro transcrip-
tion kit (Ambion, Austin, TX). Bands were visualized, cut
from the gel and quantified as counts per minute over a
five minute period with a liquid scintillation counter
(Beckman Coulter Inc., Fullerton, CA).
Reverse Transcription Polymerase Chain Reaction Analysis 
(RT-PCR)
Non-quantitative RT-PCR was performed to determine
the splice variant forms of the VEGF transcript present in
the fetal LV tissue. The ovine VEGF primers have previ-
ously been described [26]. Briefly, 5 µg of total RNA was
amplified using the Platinum® SuperScript II Single Step
RT-PCR kit (Invitrogen, Carlsbad, CA). PCR amplicons
were separated using a 0.7% agarose TBE gel and visual-
ized using an ultra violet light source.
Real Time RT-PCR
Real time RT-PCR was performed in the manner described
previously to assess relative differences of AT1 or AT2 tran-
script between C and NR fetal LV [24]. In brief, real time
RNA samples were amplified using either SYBR® Green
technology (AT1) or Taq-Man® technology (AT2) and ana-
lyzed using the ∆CT method (User Bulletin #2, Applied
Biosystems, Dec 11, 1997) and GAPDH transcript as a
normalizer. RT-PCR primers were developed for ovine
AT1 (accession# AF069750), ovine AT2 (accession#
S81979) and GAPDH (accession# AF35421) sequences,
and Taq-Man® probes for Ovine AT2 and GAPDH using
Primer Express v2.0 (Applied Biosystems, Foster City, CA)
software (Table 1). Primers and probes were synthesized
by Applied Biosystems (Foster City, CA). The RT-PCR
reactions were prepared using the Platinum® SYBR® Green
Quantitative PCR SuperMix-UDG kit (Invitrogen) for AT1
or Platinum® Quantitative PCR SuperMix-UDG kit (Invit-
rogen) for AT2 as per the manufacturer's directions.
Amplification was carried out using a Perkin-Elmer 9600
RT-PCR Machine (Perkin-Elmer) and a 2-step cycling pro-
gram (95°C for 2 min, and 45 cycles of (95°C for 15 sec,
60°C for 30 sec). RT-PCR was carried out only after the
primers had been validated across four different concen-
trations to demonstrate approximately equal amplifica-
tion efficiencies.
Western Blot Analysis
Immunoblots for detection of AT1 (306) and AT2 (H-
143) protein was performed as described in detail previ-
ously using 50 µg of total LV protein separated using SDS-
PAGE [10]. VEGF was detected in the same manner using
commercially available polyclonal antibodies VEGF (A-
20) obtained from Santa Cruz Biotechnology (Santa Cruz,
CA). All samples for each protein of interest were run in a
single assay. Immunodetection of proteins was done in
the following manner: Membranes were blocked for 1
hour in protein blocking solution (Blotto in TBS, Pierce;
Rockford, IL), then incubated in the primary antibody for
1 hour (AT1, AT2, VEGF, all at 1:500) in Blotto TBS block-
ing buffer (Pierce; Rockford, IL). All dilutions were deter-
mined empirically to achieve minimal background.
Following the primary incubation, the membrane was
washed 4 × 5 minutes each using Pierce western wash
(Pierce, Rockford, IL). The membranes were then incu-
bated in the appropriate secondary antibody; goat anti-
rabbit IgG conjugated horseradish peroxidase (SantaCruz
Biotechnology, Santa Cruz, CA) diluted to 1:1000. Fol-
lowing incubation in the secondary antibody, membranes
were washed 4 × 5 min in Pierce western wash (Pierce,
Rockford, IL). Blots were detected using a chemilumines-
Table 1: PCR primer and Taq-Man® detection probes sequences for interrogation of AT1, AT2, GAPDH by qRT-PCR.
Primer/Probe Sequence
GAPDH-1 GCA AGT TCC ACG GCA CAG T
GAPDH-2 GGT GAT GGC CTT TCC ATT GA
GAPDH-det (6FAM)AAG GTC AGA AAA CGG GAA GCT CGC TC(MGBNFQ)
AT2R-1 CAT GGA AGG GAA GCC AAC AA
AT2R-2 ACT CGT GAC CAA GTT CTG AAG ATG
AT2R-det (VIC)TGA TGA ACG CCA GAA CAA CAG CAG C(MGBNFQ)
AT1U604 CCC TTC GGC AAT TAC CTA
AT1L682 GCG GTC AAT GCT TAG ACAReproductive Biology and Endocrinology 2005, 3:27 http://www.rbej.com/content/3/1/27
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cent detection system (Supersignal® West Pico substrate,
Pierce; Rockford, IL). Membranes were incubated in
chemiluminescent substrate for 5 minutes, and exposed
to film (Kodak) from 0.5–20 min as necessary to detect
signal. Images were optically scanned (Hewlitt-Packard
5200C with HP PrecisionScan software v2.02) and digi-
tized, and antigen signal was quantified by pixel density
(Un Scan It gel v5.1; Silk Scientific, Orem, UT). Quantifi-
cation was performed only after linearity was established
between amount of protein and film exposure time. The
membrane was stripped using a commercially available
buffer (Restore, Pierce) and re-probed for detection of β-
actin at a 1:20,000 dilution (Abcam 276100, Cambridge,
UK) for use as a loading control. β-actin was detected as
described above with goat anti-mouse IgG HRP diluted to
1:40,000 (Calbiochem 401215; San Diego, CA).
Data Analysis
All data are presented as mean ± SEM. Differences in the
means between the C and NR fetuses were assessed using
independent t-tests with a Welch correction for unequal
variances if required (Prism; GraphPad Software; San
Diego, CA). Significance was accepted when P < 0.05.
Results
Animals and LV Weights
Consistent with previous reports from fetuses at 78 dGA
[6,7], no differences were observed between twin and sin-
gleton fetuses in either treatment group, or between male
and female fetuses in the control group. Sex difference
could not be assessed in the NR group. Data were there-
fore pooled to comprise the C and NR cohorts. NR fetuses
were 30% lighter than respective controls, while LV : fetal
weight ratio was increased in the NR fetuses when com-
pared to the C fetuses (Table 2, P < 0.05).
AT1, AT2, and VEGF mRNA levels
AT1 and AT2 mRNA levels were not different between the
C and NR LV as assessed by real time RT-PCR (1.099 ±
0.237 vs. 0.827 ± 0.082 and 1.075 ± 0.228 vs. 1.210 ±
0.208). LV tissue from fetuses of NR ewes had greater lev-
els of mRNA for VEGF (Figure 1) than respective C LV
when measured by RPA. The RT-PCR of total RNA from
fetal LV for VEGF splice variants indicated that VEGF165
and VEGF189 splice forms are the primary transcripts in the
LV tissue at mid-gestation (Figure 1).
AT1, AT2, and VEGF immunoreactivity
NR LV tissue had less (1918.4 ± 154.2 vs. 3881.2 ± 494.9
apu; P < 0.05) immunoreactive AT1 at 67 kDa, previously
shown to be the primary immunoreactive band in the
ovine fetal heart [18], than respective control fetal LV tis-
sue (Figure 2). The 68 kDa form of AT2, previously shown
to be the primary immunoreactive band in ovine coronary
and mesenteric arteries [27] was reduced in the NR
(1729.9 ± 293.6 vs. 3043.3 ± 373.2 apu; P < 0.05) com-
pared to the C fetuses (Figure 3). Smaller immunoreactive
Table 2: Weights and left ventricle weights of the cohort of control (C) and nutrient restricted (NR) fetuses evaluated in the present 
study.
Fetal heart weight (g) Organ wt/foetus wt (%)
Control (6) NR (6) *P Control (6) NR (6) *P
Fetus 335.1 ± 32.4 220.2 ± 10.0 0.004 -- -- --
LV 1.02 ± 0.09 0.91 ± 0.11 NS 0.31 ± 0.03 0.41 ± 0.04 0.03
*P-value control versus restricted.
Amount of VEGF mRNA relative to β-actin mRNA in the LV  of 78 dGA fetuses as determined by ribonuclease protection  assay Figure 1
Amount of VEGF mRNA relative to β-actin mRNA in the LV 
of 78 dGA fetuses as determined by ribonuclease protection 
assay. Inset picture depicts representative results of RT-PCR 
reactions for VEGF165 and VEGF189 run on a 1% agarose gel. 
NR (■ , n = 6) fetuses exhibited increased VEGF transcript in 
the LV compared to C (, n = 6) fetuses. *P < 0.05.Reproductive Biology and Endocrinology 2005, 3:27 http://www.rbej.com/content/3/1/27
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bands, the exact identity of which remains unclear, were
observed for both AT1 and AT2. No differences were
observed between the C and NR groups in these smaller
immunoreactive bands (data not shown). These smaller
bands could be either the non-glycosylated form that has
been reported previously or a degradation product [28].
VEGF was visualized as two immunoreactive bands (46
and 54 kDa) when evaluated under reducing conditions
(Figure 4). Total VEGF protein (sum of both bands) was
not different between the C and NR LV (1278 ± 164 vs.
860 ± 89 apu; P = 0.11). The same result was revealed by
further analysis of each band separately (46 kDa, 767 ± 99
vs. 576 ± 60, P = 0.14; 54 kDa, 511 ± 73 vs. 384 ± 40 apu,
P = 0.15; Figure 4)
Discussion
In the present study we have examined cardiac LV tissue
obtained from ovine fetuses at 78 dGA generated using an
established model of maternal NR-induced growth restric-
tion in which heart weight is protected [6] We have tested
the hypothesis that the increase LV mass relative to fetal
body weight following global maternal NR during early to
mid-gestation is associated with increases in the expres-
sion of VEGF and the intra-cardiac renin-angiotensin sys-
tem receptors. In addition to confirming both the IUGR
and preservation of heart mass previously reported, the
principle findings of this study are that the LV of NR
fetuses demonstrates: 1) decreased AT1 and AT2 protein
without a decrease in AT1 and AT2 mRNA; and 2)
increased VEGF mRNA without an increase in total VEGF
protein; leading to the conclusion that VEGF and the
intra-cardiac renin-angiotensin system receptors are not
directly involved in the protection of left ventricular mass
observed in this model.
The primary objectives in the present work centered on
characterizing alterations in expression of specific genes in
the fetal LV that are induced by global maternal NR during
early to mid-gestation in the fetal sheep. Consequently tis-
sues were captured specifically for this purpose. Recent
work has shown nearly all cardiomyocytes are mono-
nucleated at mid-gestation, and that conversion to the
mature, bi-nucleate state do not begin in earnest until
approximately 120 dGA in sheep [29]. A change in cardi-
omyocyte size appears to be strongly related to conversion
to bi-nucleated status and is therefore also a phenomenon
of late gestation [29]. Since we were interested in evaluat-
ing mid-gestation alterations in the fetal LV that might
contribute to persistent changes in heart development and
function, we chose to evaluate VEGF and the AngII recep-
tors rather than to perform detailed morphometric analy-
sis at this early stage in myocardial development.
Histological evaluation of both the mono-nucleate : bi-
nucleate ratio and cardiomyocyte size and volume never-
theless remain an important future objective.
Fetuses from NR (■ , n = 6) ewes demonstrated less AT1  expression than C (, n = 6) LV Figure 2
Fetuses from NR (■ , n = 6) ewes demonstrated less AT1 
expression than C (, n = 6) LV. Inset depicts representative 
immunoblot for AT1 and β-actin. Equal protein loading 
between lanes was demonstrated by re-probing membranes 
for β-actin. *P < 0.05.
Fetuses derived from NR (■ , n = 6) ewes exhibited  decreased AT2 expression in the LV compared to fetuses  from the C (, n = 6) ewes Figure 3
Fetuses derived from NR (■ , n = 6) ewes exhibited 
decreased AT2 expression in the LV compared to fetuses 
from the C (, n = 6) ewes. Inset depicts representative 
immunoblot for AT2 and β-actin. Equal protein loading 
between lanes was demonstrated by re-probing membranes 
for β-actin. *P < 0.05.Reproductive Biology and Endocrinology 2005, 3:27 http://www.rbej.com/content/3/1/27
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Angiotensin II Signalling
AngII signaling is involved in cardiac growth, largely
through hyperplastic mechanisms in both myocytes and
fibroblasts [16,18,19]. Previous work has shown distinct
patterns of AT1 and AT2 mRNA and protein expression
during fetal heart development in the sheep [14,29]. At
the sub-cellular level, AT1 and AT2 mediate effects
through disparate means. Whereas AT1 activates multiple
signal pathways including calcium, phospholipids,
kinases and reactive oxygen species, the AT2 receptor is
typically linked to pathways such as phosphatases and
protein dephosphorylation, and nitric oxide [30]. That
AT1 activates kinases while AT2 activates phosphatases
provides a general indication of the present notion that
the two receptors are often antagonistic [31].
We show no change in mRNA levels of the AT1 and AT2
receptors. These observations are consistent with the pre-
vious report in the same cohort of animals [7] and those
of others studying sheep [32]. In contrast, Kijima et al.
have reported increased expression of AT1 and AT2 mRNA
and protein in neonatal rat cardiomyocytes stretched in
vitro [33]. The present data, viewed in concert with the
above studies and the previous work by Edwards showing
increased fetal blood pressure in NR fetuses [13], suggests
that the nutrient restricted ovine fetal heart may be subject
to increased afterload rather than volume overload.
Interestingly, we report that AT1 and AT2 are decreased at
the protein level with no change in mRNA expression for
these proteins. Previous work has shown AT1 and AT2
Fetuses derived from NR (■ , n = 6) ewes exhibited no difference in total immunoreactive VEGF, or immunoreactive VEGF165  (46 kDa) or VEGF189 (54 kDa) isoforms in the LV compared to fetuses from the C (, n = 6) ewes Figure 4
Fetuses derived from NR (■ , n = 6) ewes exhibited no difference in total immunoreactive VEGF, or immunoreactive VEGF165 
(46 kDa) or VEGF189 (54 kDa) isoforms in the LV compared to fetuses from the C (, n = 6) ewes. Inset depicts representative 
immunoblot for VEGF and β-actin. Equal protein loading between lanes was demonstrated by re-probing membranes for β-
actin.Reproductive Biology and Endocrinology 2005, 3:27 http://www.rbej.com/content/3/1/27
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mRNA and protein demonstrate negative regulation fol-
lowing AngII exposure in vitro at several different levels,
including transcriptional and post-translational [34,35].
While little work has been done to evaluate protein
expression of AT1 in the fetus, contemporary literature
acknowledges the existence of regulatory points for trans-
lational and post-translational control of AT1 expression
that support a discordance between protein and mRNA
for AT1 [36,37]. Neither circulating nor tissue AngII con-
centrations were measured in the present study, however
circulating AngII does not figure prominently in the regu-
lation of the cardiac AngII receptors since cardiac intersti-
tial AngII is typically over 100 fold higher in
concentration than plasma AngII [38]. Consequently, the
present observations may indicate that chronically aug-
mented intra-cardiac AngII production exists in the LV of
the NR fetus since receptor protein expression was inhib-
ited in this group compared to the C group.
The decrease in immunoreactive AT1 suggests that regard-
less of the type of growth occurring (i.e. hyperplasia,
hypertrophy or extracellular matrix proliferation), alterna-
tive mechanisms to AT1 signaled growth must be opera-
tive in the NR fetus. Previous work has shown that, when
AT1 receptors are absent, hypertrophic stimuli act via
induction of tyrosine kinase pathways [39]. This observa-
tion may explain why in vivo blockade of AT1 receptors
during pressure overload does not completely attenuate
ventricular hypertrophy in the late gestation fetal sheep
[18]. Similarly, the present findings are consistent with
previous work showing that hypertrophic responses in
neonatal cardiomyocytes induced by mechanical stretch
are not ablated by AT1 inhibition [40]. Alternatively, in
light of the recent work by Sundgren et al. [16], the
observed decrease of AT1 in the NR LV may result in
reduced proliferation of cardiomyocytes and conse-
quently an impaired myocyte endowment in the NR ani-
mal, thereby contributing to reduce cardiovascular
function and reserve in later life [41,42].
Although the actions of AT2 in the fetal heart remain neb-
ulous, present evidence indicates AT2 regulates cell
growth in cultured fetal cardiomyocytes [43]. AT2 is also
recognized as a promoter of vasodilation [44]. The
observed reduction of AT2 in the NR heart may therefore
represent a development deficit in vasodilatory capacity
and/or accelerated maturation of the coronary circulation.
This is in part consistent with observations by Nishina et
al. who reported impaired vasodilatory responses in fem-
oral resistance arteries from undernourished sheep fetuses
at mid-gestation [45]. Unfortunately, the limited tissue
availability from the present study did not allow for recep-
tor localization via immunohistochemistry. As with the
AT1 receptor, we report a discord between gene transcrip-
tion and immunoreactive AT2 in the NR fetal LV. Recent
work examining the kidneys of offspring from protein
restricted rat dams shows AT2 mRNA increases while AT2
protein expression is decreased; however no mechanisms
have been described or proposed for this observation
[46]. Clearly, further work is needed to thoroughly inves-
tigate these observations.
Vascular Endothelial Growth Factor
Because of the observed preservation of LV mass in the
face of IUGR, one might suspect an increase in VEGF
expression to provide adequate vascularity to the aug-
mented cardiac tissue mass. VEGF is thought to be
involved in compensatory coronary vascular growth since
its expression is increased in the hypertrophied hearts of
spontaneously hypertensive rats and in experimental
models of pressure overload [47,48]. The existence of
heparin binding domains alters VEGF solubility and has
profound impacts upon its activity/function. VEGF165
contains 1 heparin binding region and therefore has lim-
ited solubility, while VEGF189 is not freely diffusible and
binds tightly to the extra cellular matrix [49]. We have
shown that both VEGF165 and VEGF189 protein were con-
firmed present using isoform specific RT-PCR. Since
VEGF165 has limited solubility and VEGF189 is not soluble,
it is not likely that the observed discordance between
mRNA and immunoreactive protein is a consequence of
translated VEGF being secreted and transported away
from the heart in the circulation. Moreover, we have
previously reported in sheep that fetal plasma VEGF at
mid-gestation is not altered by maternal NR [6]. Finally,
the discordance between VEGF transcription and transla-
tion reported in this study agrees with previous data by
others in adult rat cardiac tissue [50]. Furthermore, acute
increases in afterload in the fetal sheep by means of a 7
day infusion of Ang II results in ventricle hypertrophy
without increases in VEGF mRNA expression [19]. In fact,
these authors reported that phenylephrine infusion
decreased VEGF mRNA in the fetal LV and RV while ven-
tricular mass increased. Unfortunately protein expression
was not investigated. Nonetheless, these data collectively
suggest that VEGF is not directly involved in preserving LV
mass relative to fetal body weight at mid-gestation follow-
ing maternal NR.
We have previously identified an increase in gene tran-
scription for a recently described neuropilin-1 like protein
[51], endothelium derived smooth muscle neuropilin
(ESDN), in the NR fetal LV [7]. Neuropilin-1 has been
found to facilitate VEGF165 signaling. Since the activities of
ESDN have not been fully characterized, at least to our
knowledge, we cannot rule out the possibility that ESDN
may possess neuropilin-1 like properties. If ESDN protein
is increased along with gene transcription, VEGF165 activ-
ity may be increased without a concomitant increase in
protein. Without further insight into the function ofReproductive Biology and Endocrinology 2005, 3:27 http://www.rbej.com/content/3/1/27
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ESDN as it relates to VEGF, we interpret the present find-
ings to mean that VEGF protein expression is not inti-
mately involved in the observed preservation of
ventricular weight. We further suggest that this observa-
tion may allow for the development of a vascular deficit
in the fetal myocardium following NR.
VEGF and the Intracardiac Renin-Angiotensin System
Previous investigators have described an interaction
between the renin-angiotensin system and VEGF systems
in several adult animal species. Recent work has demon-
strated that Ang II exerts pro-angiogenic effects via the AT1
receptor and VEGF in mice [52], while AT1 inhibition is
shown to impair VEGF mediated coronary angiogenesis in
hamsters [23]. Similarly, Sarlos et al. have shown that AT2
interacts with VEGF in the promotion of angiogenesis in
the fetal rat retina [53]. The lack of change in VEGF pro-
tein in the present study may therefore be a result of the
reduced expression of AT1 and/or AT2 in the fetal LV.
Since evaluation of the systems that lie downstream of
AT1 and AT2 is beyond the means of the present work,
further studies are necessary to determine if this is indeed
the case in the present model.
Limitations
The present study has several limitations. The origin of the
protection of cardiac LV mass (i.e. hypertrophy, hyperpla-
sia or extracellular matrix) remains unclear and further
experiments should be undertaken to evaluate this prop-
erly. With respect to the observed discordance between
gene transcription and protein expression, it should be
noted that one cannot discount the possibility that novel
regulatory mechanisms may be at work in the fetus when
compared to the adult. Interrogation of the discord is
unfortunately beyond the scope of the present work and
tissue availability at this time. Finally, it remains unclear
whether differences between male and female fetuses exist
during normal fetal cardiac development, and whether sex
differences may contribute to the present differences in
the gene transcription and protein expression in response
to maternal NR in this study.
Conclusion
We have demonstrated decreased immunoreactive AT1
and AT2 receptor protein without a decrease in mRNA,
and increased VEGF mRNA with no change in VEGF pro-
tein, in the fetal LV at mid-gestation. As a result of these
findings, we reject the hypothesis that VEGF and the
renin-angiotensin system [via AT1 and AT2] are primary
mediators of the observed protection of LV mass in the NR
fetuses. Furthermore, these data show no evidence of a
compensatory increase in VEGF protein expression that
would be expected concomitant with the augmented LV :
fetal weight ratio. We postulate that the mechanisms
underlying the discord between gene transcription and
protein expression for both VEGF and AT1/AT2 may
involve decreased translational efficiency or increased
protein turnover. The present findings may contribute an
important first step towards elucidating mechanisms
underlying epidemiological studies that indicate fetuses
with low birth weight carry an increased risk of mortality
from cardiovascular disease, particularly if these individu-
als have reduced cardiovascular reserve due to an epige-
netic decrease in vascularization. While these results are
intriguing, the scope of these findings is narrow and fur-
ther experiments are needed to place these data into
perspective.
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